Cargando…

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix

OBJECTIVE: This study was designed to describe the course of IgG/IgA responses in cervical secretions and in serum one year after the first dose of intramuscular administration of the HPV16/18 AS04-adjuvant vaccine. METHODS: Blood and cervical mucus samples were collected for immunologic assays, 7 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Ana Paula Ferreira, Gonçalves, Ana Katherine, Machado, Paula Renata Lima, de Souza, Luanda B. F. C., Sarmento, Ayane, Cobucci, Ricardo Ney Oliveira, Giraldo, Paulo César, Witkin, Steven S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171383/
https://www.ncbi.nlm.nih.gov/pubmed/30141308
http://dx.doi.org/10.22034/APJCP.2018.19.8.2313
_version_ 1783360778250747904
author Costa, Ana Paula Ferreira
Gonçalves, Ana Katherine
Machado, Paula Renata Lima
de Souza, Luanda B. F. C.
Sarmento, Ayane
Cobucci, Ricardo Ney Oliveira
Giraldo, Paulo César
Witkin, Steven S
author_facet Costa, Ana Paula Ferreira
Gonçalves, Ana Katherine
Machado, Paula Renata Lima
de Souza, Luanda B. F. C.
Sarmento, Ayane
Cobucci, Ricardo Ney Oliveira
Giraldo, Paulo César
Witkin, Steven S
author_sort Costa, Ana Paula Ferreira
collection PubMed
description OBJECTIVE: This study was designed to describe the course of IgG/IgA responses in cervical secretions and in serum one year after the first dose of intramuscular administration of the HPV16/18 AS04-adjuvant vaccine. METHODS: Blood and cervical mucus samples were collected for immunologic assays, 7 months after the first doses and 1 year following the last boost vaccination (month 7) by enzyme linked immunosorbent assay (ELISA). The detection of IgG and IgA anti-HPV/VLP was developed for this purpose. RESULT: A total of 100% of serum samples were IgG antibody positive at a titer of 1:100 at both time periods and decreased according to the serum dilution. For serum IgA antibody, 95% were positive one month after vaccination and 79% were positive 1 year later. Similar results were observed with the cervical samples positive for both IgG and IgA antibodies at one month and decreasing after 1 year to 33% and 29%. The median absorbance in serum and the cervix for IgG and IgA anti-HPV-VLP antibodies was significantly higher at one month after vaccination when compared to 1 year post-vaccination (P<0.0001). CONCLUSION: Immune responses were significant one year after immunization, however it decreased in cervical and serum samples when compared to levels observed one month after the last dose. This suggests that a vaccine booster may be necessary to increase antibody titers.
format Online
Article
Text
id pubmed-6171383
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-61713832018-10-15 Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix Costa, Ana Paula Ferreira Gonçalves, Ana Katherine Machado, Paula Renata Lima de Souza, Luanda B. F. C. Sarmento, Ayane Cobucci, Ricardo Ney Oliveira Giraldo, Paulo César Witkin, Steven S Asian Pac J Cancer Prev Research Article OBJECTIVE: This study was designed to describe the course of IgG/IgA responses in cervical secretions and in serum one year after the first dose of intramuscular administration of the HPV16/18 AS04-adjuvant vaccine. METHODS: Blood and cervical mucus samples were collected for immunologic assays, 7 months after the first doses and 1 year following the last boost vaccination (month 7) by enzyme linked immunosorbent assay (ELISA). The detection of IgG and IgA anti-HPV/VLP was developed for this purpose. RESULT: A total of 100% of serum samples were IgG antibody positive at a titer of 1:100 at both time periods and decreased according to the serum dilution. For serum IgA antibody, 95% were positive one month after vaccination and 79% were positive 1 year later. Similar results were observed with the cervical samples positive for both IgG and IgA antibodies at one month and decreasing after 1 year to 33% and 29%. The median absorbance in serum and the cervix for IgG and IgA anti-HPV-VLP antibodies was significantly higher at one month after vaccination when compared to 1 year post-vaccination (P<0.0001). CONCLUSION: Immune responses were significant one year after immunization, however it decreased in cervical and serum samples when compared to levels observed one month after the last dose. This suggests that a vaccine booster may be necessary to increase antibody titers. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6171383/ /pubmed/30141308 http://dx.doi.org/10.22034/APJCP.2018.19.8.2313 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Costa, Ana Paula Ferreira
Gonçalves, Ana Katherine
Machado, Paula Renata Lima
de Souza, Luanda B. F. C.
Sarmento, Ayane
Cobucci, Ricardo Ney Oliveira
Giraldo, Paulo César
Witkin, Steven S
Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title_full Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title_fullStr Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title_full_unstemmed Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title_short Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
title_sort immune response to human papillomavirus one year after prophylactic vaccination with as04-adjuvanted hpv-16/18 vaccine: hpv-specific igg and iga antibodies in the circulation and the cervix
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171383/
https://www.ncbi.nlm.nih.gov/pubmed/30141308
http://dx.doi.org/10.22034/APJCP.2018.19.8.2313
work_keys_str_mv AT costaanapaulaferreira immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT goncalvesanakatherine immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT machadopaularenatalima immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT desouzaluandabfc immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT sarmentoayane immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT cobucciricardoneyoliveira immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT giraldopaulocesar immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix
AT witkinstevens immuneresponsetohumanpapillomavirusoneyearafterprophylacticvaccinationwithas04adjuvantedhpv1618vaccinehpvspecificiggandigaantibodiesinthecirculationandthecervix